Delayed-onset neutropenia associated with rituximab therapy
- Autores: Alekseeva Y.A1, Vabishchevich R.I1
-
Afiliações:
- Edição: Nº 18 (2012)
- Páginas: 62-65
- Seção: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/280002
- ID: 280002
Citar
Texto integral
Acesso aberto
Acesso está concedido
Acesso é pago ou somente para assinantes
Resumo
Delayed-onset neutropenia (DON) is a rare condition often occurring without a high risk of infection. Genesis of this condition is poorly understood; release of antineutrophil antibodies, inhibition of neutrophils through the formation of large granular lymphocytes, granulocytes maturation change after reconstitution of B-cell lines, and cytokine desregulation are considered as possible mechanisms of development. In some cases, DON occurs in patients receiving rituximab. Currently, clinical experience indicate the possibility of reinitiation of therapy with rituximab after resolution of DON.
Palavras-chave
Texto integral
Bibliografia
- Coiffier B., Lepage E., Briere J., et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large ß-cell lymphoma. N Eng J Med 2002;346:235-42.
- Dunleavy K., Tay K., Wilson W.H. Rituximab-assotiated neutropenia. Semin Hematol 2010;47(2):180-86.
- Dunleavy K., Hakim F., Kim H.K., et al. β-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis. Blood 2005;106(3):795-802.
- Besada E., Koldingsnes W., Nossent J. Characteristics of late onset neutropenia in rheumatologic patients treated with rituximab: a case review analysis from a single center. QJM 2012;105(6):545-50.
- Tesfa D., Ajeganova S., Hagglund H., et al. Late-onset neutropenia following rituximab therapy in rheumatic diseases: Association with B-lymphocyte depletion and infections. Arthritis Rheum 2011;63(8):2009-14.
- Terrier B., Ittah M., Tourneur L., et al. Late-onset neutropenia following rituximab results from a hematopoietic lineage competition due to an excessive BAFF-induced β-cell recovery. Haematologica 2007;92(2):e20-3.
- Marinos L., Economaki E., et al. T-LGL related neutropenia. The 3rd Neutropenia Network Conference. Hematology Meeting Reports 2008;2(3).
- Kim M., Lee J.K., Hong Y.J., et al. Late-onset neutropenia following rituximab therapy as a treatment of diffuse large β-cell lymphoma: a single institution study. Korean J Lab Med 2010;30(6):575-79.
- Kimby E. Tolerability and safety of rituximab. Cancer Treat Rev 2005;31:456-73.
- Ram R., Ben-Bassat I., Shpilberg O., et al. The late adverse events of rituximab therapy: Rare but there! Leuk Lymphoma 2009;50:1083-95.
Arquivos suplementares
